92 related articles for article (PubMed ID: 12006769)
1. Tumor cell motility as a novel target in cancer--experimental and clinical results.
Otto T; Luemmen G; Bex A; Suhr J; Goebell PJ; Raz A; Ruebben H
Onkologie; 2002 Apr; 25(2):172-7. PubMed ID: 12006769
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell motility. A novel therapeutic target in bladder carcinoma, experimental and clinical results.
Otto T; Lümmen G; Be A; Rübben H; Raz A
Adv Exp Med Biol; 1999; 462():469-76. PubMed ID: 10599448
[TBL] [Abstract][Full Text] [Related]
3. Motility- and adhesion factors in bladder carcinoma.
Otto T; Goepel M; Enzwi SM; Meyer-Schwickerath M; Rübben H
Investig Urol (Berl); 1994; 5():80-4. PubMed ID: 7719326
[No Abstract] [Full Text] [Related]
4. [Principles of tumor invasion and metastasis].
Otto T; Goepel M; Recker F; Rübben H
Urologe A; 1995 May; 34(3):208-11. PubMed ID: 7610514
[TBL] [Abstract][Full Text] [Related]
5. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder.
Korman HJ; Peabody JO; Cerny JC; Farah RN; Yao J; Raz A
J Urol; 1996 Jan; 155(1):347-9. PubMed ID: 7490884
[TBL] [Abstract][Full Text] [Related]
6. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
7. Improved prognosis assessment for patients with bladder carcinoma.
Otto T; Bex A; Schmidt U; Raz A; Rübben H
Am J Pathol; 1997 Jun; 150(6):1919-23. PubMed ID: 9176385
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for bladder cancer.
Otto T; Goepel M; Heider KH; Rübben H
Urol Res; 1995; 23(3):137-41. PubMed ID: 7483138
[TBL] [Abstract][Full Text] [Related]
9. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
10. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas.
Otto T; Birchmeier W; Schmidt U; Hinke A; Schipper J; Rübben H; Raz A
Cancer Res; 1994 Jun; 54(12):3120-3. PubMed ID: 8205527
[TBL] [Abstract][Full Text] [Related]
11. [Urothelial carcinoma. Role of G-protein coupled receptors in cell movement and proliferation].
Lümmen G; Sperling H; Schneider T; Otto T; Rübben H
Urologe A; 2002 Jul; 41(4):353-61. PubMed ID: 12214453
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of thymosin β4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma.
Wang ZY; Zeng FQ; Zhu ZH; Jiang GS; Lv L; Wan F; Dong R; Xiao XY; Xing SA
Urol Oncol; 2012; 30(2):167-76. PubMed ID: 20864366
[TBL] [Abstract][Full Text] [Related]
13. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion.
Garg M; Kanojia D; Seth A; Kumar R; Gupta A; Surolia A; Suri A
Eur J Cancer; 2010 Jan; 46(1):207-15. PubMed ID: 19914824
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a newly established human bladder carcinoma cell line, NTUB1.
Yu HJ; Tsai TC; Hsieh TS; Chiu TY
J Formos Med Assoc; 1992 Jun; 91(6):608-13. PubMed ID: 1358347
[TBL] [Abstract][Full Text] [Related]
15. Human urinary bladder cancer T24 cells are susceptible to the Antrodia camphorata extracts.
Peng CC; Chen KC; Peng RY; Su CH; Hsieh-Li HM
Cancer Lett; 2006 Nov; 243(1):109-19. PubMed ID: 16455193
[TBL] [Abstract][Full Text] [Related]
16. Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway.
Wang W; Chen H; Liu Z; Qu P; Lan J; Chen H; Zou L; Qiu J
Br J Cancer; 2016 Feb; 114(3):305-13. PubMed ID: 26742010
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma.
Endo K; Shirai A; Furukawa M; Yoshizaki T
Hum Pathol; 2006 Aug; 37(8):1111-6. PubMed ID: 16867875
[TBL] [Abstract][Full Text] [Related]
18. Autocrine motility factor receptor gene expression and cell motility in lung cancer cell lines.
Takanami I; Takeuchi K; Watanabe H; Yanagawa T; Takagishi K
Oncol Rep; 2002; 9(1):125-8. PubMed ID: 11748469
[TBL] [Abstract][Full Text] [Related]
19. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies.
Bryan RT; Atherfold PA; Yeo Y; Jones LJ; Harrison RF; Wallace DM; Jankowski JA
J Pathol; 2008 Jun; 215(2):184-94. PubMed ID: 18393367
[TBL] [Abstract][Full Text] [Related]
20. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
Wirger A; Perabo FG; Burgemeister S; Haase L; Schmidt DH; Doehn C; Mueller SC; Jocham D
Anticancer Res; 2005; 25(6B):4341-7. PubMed ID: 16309238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
